Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAPEO.L Regulatory News (APEO)

  • There is currently no data for APEO

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Edison issues review on Abrdn Private Equity Opp.

9 Aug 2022 07:00

RNS Number : 3005V
abrdn Private Equity Opp Trst plc
09 August 2022
 

London, UK, 9 August 2022

 

Edison issues review on Abrdn Private Equity Opportunities Trust (APEO)

Abrdn Private Equity Opportunities Trust (APEO) posted a 6.8% NAV total return (TR) in H122 (ending March 2022), which was a function of a robust return in late 2021 (in calendar Q421 at 5.2%, driven by profitable exits). The NAV TR between end-December 2021 and end-June 2022 stands at 2.4%, but its latest NAV is still largely based on end-March 2022 valuations and does not capture the subsequent sell-off in public equities. APEO's manager acknowledges that macro headwinds are likely to exert pressure on corporate earnings and portfolio valuations in H222. We note that this has already been reflected in its share price as APEO's discount to NAV widened to c 39% (versus 20% in our February 2022 note).

 

We note that APEO invests primarily in PE mid-market funds with a typical size of €1.0-5.0bn AUM (and has lately put more emphasis on lower mid-market funds of €150m to €1.0bn), which in recent years have accumulated less capital than PE 'megafunds'. Therefore, mid-market funds are likely to see a less demanding competition for acquisition targets. At the same time, mid-market funds tend to be less dependent on IPOs as an exit route, which may help sustain a good level of distributions to APEO despite the market headwinds. APEO's commitment coverage ratio has decreased recently to 26% (from a 43% monthly average over the last two years), but we view this as a safe level (see below). APEO's board is also confident that the company can continue its dividend policy, with 3.6p to be paid in October 2022 and January 2023, implying an annualised yield of 3.3%. 

Click here to view the full report or here to sign up to receive research as it is published.

 

All reports published by Edison are available to download free of charge from its website

www.edisongroup.com

About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors. By focusing on the volume and quality of investors reached - across institutions, family offices, wealth managers and retail investors - Edison can create and gauge intent to purchase, even in the darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings.

Having been the first in-market 17 years ago, Edison now has more than 100 analysts covering every economic sector. Headquartered in London, Edison also has offices in New York, Frankfurt, Amsterdam and Tel Aviv and a presence in Athens, Johannesburg and Sydney.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information, please contact Edison:

Milosz Papst +44 (0)20 3681 2519 investmenttrusts@edisongroup.com

Michal Mordel +44 (0)20 3077 5700 investmenttrusts@edisongroup.com

Learn more at www.edisongroup.com and connect with Edison on: 

LinkedIn https://www.linkedin.com/company/edison-group-/

Twitter www.twitter.com/Edison_Inv_Res

YouTube www.youtube.com/edisonitv

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAZVLFBLVLFBBQ
Date   Source Headline
30th Apr 202410:48 amRNSDirector/PDMR Shareholding
29th Apr 20244:53 pmRNSChange of Name
17th Apr 20247:00 amRNSEstimated NAV at 31 March 2024
16th Apr 202410:26 amRNSDirector/PDMR Shareholding
15th Apr 20244:51 pmRNSUpdate from QuotedData
8th Apr 20247:00 amRNSTransaction in Own Shares
3rd Apr 20244:37 pmRNSQuarterly disclosure
2nd Apr 20247:00 amRNSTotal Voting Rights
27th Mar 20243:50 pmRNSResult of AGM and Investment Manager Update
19th Mar 20247:00 amRNSEstimated NAV at 29 February 2024
13th Mar 20247:00 amRNSFirst Interim Dividend
11th Mar 20247:00 amRNSTransaction in Own Shares
4th Mar 20242:07 pmEQSEdison issues update on abrdn Private Equity Opportunities Trust (APEO): Returns and buyback help narrow the discount
26th Feb 20247:00 amRNSTransaction in Own Shares
19th Feb 20247:00 amRNSTransaction in Own Shares
16th Feb 20247:00 amRNSEstimated NAV at 31 January 2024
5th Feb 20247:00 amRNSTransaction in Own Shares
31st Jan 20247:00 amRNSAnnual Financial Report
30th Jan 20241:13 pmRNSDirector/PDMR Shareholding
25th Jan 20247:00 amRNSShare Buyback Programme
17th Jan 20247:00 amRNSEstimated NAV at 31 December 2023
12th Jan 20247:00 amRNSNotice of Results
5th Jan 20249:03 amRNSQuarterly disclosure
19th Dec 20237:00 amRNSEstimated NAV at 30 November 2023
14th Dec 20231:14 pmRNSReplacement - Fourth Interim Dividend
13th Dec 20237:00 amRNSFourth Interim Dividend
15th Nov 20237:00 amRNSEstimate NAV at 31 October 2023
31st Oct 20232:32 pmRNSHolding(s) in Company
31st Oct 20232:31 pmRNSHolding(s) in Company
31st Oct 20232:30 pmRNSHolding(s) in Company
31st Oct 202310:36 amRNSDirector/PDMR Shareholding
25th Oct 202311:34 amEQSEdison issues update on abrdn Private Equity Opportunities Trust (APEO): Resilient NAV and stable balance sheet
18th Oct 20237:00 amRNSEstimated NAV at 30 September 2023
16th Oct 202311:09 amRNSStatement regarding Investment Manager
6th Oct 20234:16 pmRNSQuotedData's Weekly News & Interview
4th Oct 20239:08 amRNSQuarterly disclosure
25th Sep 20237:00 amRNSEstimate NAV at 31 August 2023
14th Sep 20237:00 amRNSThird Interim Dividend
12th Sep 20239:56 amRNSAnnual Overview from QuotedData
18th Aug 20234:11 pmRNSHolding(s) in Company
15th Aug 20237:00 amRNSEstimated NAV at 31 July 2023
1st Aug 20233:09 pmRNSDirector/PDMR Shareholding
18th Jul 202312:11 pmRNSEdison issues update on abrdn PEO Trust
17th Jul 20237:00 amRNSEstimated NAV at 30 June 2023
7th Jul 20237:00 amRNSDoc re. Half Yearly Report
5th Jul 20239:19 amRNSQuarterly disclosure
28th Jun 20239:16 amRNSHalf-year Report - Replacement
28th Jun 20237:00 amRNSHalf-year Report
20th Jun 20237:00 amRNSEstimated NAV at 31 May 2023
14th Jun 20237:00 amRNSSecond Interim Dividend

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.